Medicinal and Process Chemistry Consultant: Drug Discovery, Drug Development and Intellectual Property Evaluations.

Technical Consultant #1603


  • Technology transfer and business plan development.
  • Marketing and contracts.
  • Medicinal chemistry drug discovery.
  • Catalytic methods to control stereochemistry.
  • Pharmaceutical lead optimization and testing.
  • Intellectual property management.
  • Structure-based drug design.
  • Peptide chemistry.
  • Preclinical development.
  • cGMP chemical process development.
  • Preparation of CMC section of IND.
  • Outsourcing and partnering of medicinal chemistry.
  • Scientific proposal writing for government funding.


Undisclosed Company, Director of Chemistry, 2010 - Present

  • Leading entrepreneurial, intellectual property and technology development for programs directed at hepatitis B, liver cancer, or multiple viruses.
  • Directed the technical feasibility, contributed to business plan development, provided input into the contract negotiations, and coordinated logistics for the donation of a large pharmaceutical research laboratory - natural product collection.
  • Developed marketing plan for the Natural Products Discovery Institute, resulting in initial funding from the NIH and interest from multiple Clients.
  • Performing business development activities related to acquiring assets supportive of anti-viral programs.
  • Filed, received, and implemented state innovation grants to support our drug discovery and diagnostic programs.
  • Proposed a new anti-viral project in collaboration with Drexel University to develop PI3K p110 Delta kinase inhibitors that block host cell signally pathways important for viral replication. This project was funded by a Pennsylvania DCED Innovation Grant.

Undisclosed Company, Founder and Director of Chemistry, 2008 - Present

  • Performed synthetic studies that determined the identity of the major human metabolite of JWH-018, a synthetic cannabinoid agonist, and provided reference material for LC method development.
  • Prepared Drug Discovery due diligence reports and research proposals for business development opportunities (CNS, Pain, Oncology, and Metabolic Disease) within major Pharmaceutical Company to facilitate their decisions on the technologies.
  • Directed the outsourcing of medicinal chemistry to Eastern Europe and Asia resulting in diverse libraries of well characterized compounds.
  • Provide medicinal chemistry advice for Biotechnology Companies, Pharmaceutical Companies, and Academic Groups.
  • Involved with SBIR proposal writing, lead design/optimization, literature searching, and mechanism of action investigations, biotechnology company start-up, and freedom to operate evaluations.

Johnson & Johnson, Spring House, PA, Research Fellow, 2000 - 2007

  • Identified drug candidate; an alpha-v beta-3/5 integrin antagonist with oral efficacy in animal models of eye disease.
  • Experimentally determined absolute stereochemistry of a medicinal compound by a combination of x-ray crystallography and synthesis.
  • Implemented and researched collaborative project with J-Star Research to improve process efficiency and throughput for scale-up.
  • Worked with a homogeneous catalysis contractor (Johnson-Matthey) to attain excellent stereocontrol and low catalyst loading.
  • Investigated experimentally a novel organocatalytic method to control two stereocenters simultaneously.
  • Identified a 2-azabicyclo[2.2.2]octane-based alpha-4 beta-1 integrin antagonist as an inhaled anti-asthmatic agent and put together compound monograph for compound development recommendation.
  • Identified the minimum structural requirements for activation of the urotensin-II receptor by its peptide ligand, therefore generating a novel ligand for use in HTS.
  • Developed multiple, novel series of small-molecule U-II receptor antagonists with single-digit nanomolar potency utilizing structure based drug design.
  • Currently preparing a Perspective Article for J. Med. Chem. on the Urotensin-II Field.
  • Wrote a postdoctoral research proposal, recruited a scientist, and participated in a project that identified self-assembling collagen-mimetic peptides with thrombogenic properties.
  • Initiated collaboration with Cresset Biomolecular to quantify-stacking interactions, which led to three scientific papers in high-impact journals and potential practical applications.

Magainin Pharmaceuticals, Plymouth Meeting, PA, 1993 - 1999

  • Inventor on two new molecular entities (NME's) that moved into clinical development: Squalamine and trodusquemine.
  • Developed SAR on the anti-infective properties of squalamine, other natural aminosterols, and analogs.
  • Redirected resources towards the development of a practical 16-step synthesis of squalamine.
  • Experimentally developed a practical method of converting squalamine to trodusquemine and produced material for in vivo characterization.
  • Outsourcing: Selected five external manufacturers and negotiated contracts to define intellectual property ownership, scope of project, deliverables, and specifications on intermediates and final products to meet budgetary and time line criteria.
  • cGMP synthesis: Completed production of GMP squalamine drug substance on time and on budget to initiate Phase I clinical trials in oncology.
  • Regulatory filings: Prepared the Chemistry Manufacturing and Controls section of the IND on squalamine lactate, as part of the IND Project Team.
  • Led project team (chemistry and biology) on the centrally acting anti-obesity agent trodusquemine.
  • Applied for and received a Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI) to develop an abbreviated route to squalamine.

Wyeth-Ayerst Laboratories, Princeton, NJ, 1989 - 1993

  • Designed and synthesized a structurally unusual NMDA-antagonist (Perzinfotel; EAA-090) under trial for the treatment of neuropathic pain.

Honors & Publications

Academic and Professional Affiliations

  • Invited speaker at 12 scientific meetings or universities.
  • Manuscript reviewer: J. Am. Chem. Soc., J. Med. Chem., Tetrahedron Lett., J. Org. Chem., Org. Lett., Synlett, Lett. Drug Design Discov., Bioconj. Chem., and Peptides.
  • Co-chaired the Symposium on Polyamines at the 209th ACS National Meeting
  • Participated in Ph.D. defense committees at Brown, Lehigh, and Villanova Universities.
  • Developed a Lead Optimization Project Champion Training course and organized an internal Science Day Symposium
  • Member, organizing committee, 13th Symposium on the Latest Trends in Organic Synthesis, Brock University, St. Catherine's, Ontario.
  • Member, Study Section for Eye & Vision, to review proposals for grants from the U. S. Government.
  • Invited Editor, Current Topics in Medicinal Chemistry to develop special issue dedicated to the various aspects of patent law and their impact on medicinal chemistry.

Publications and Patents

  • Author on 50 scientific publications, in print.
  • Inventor of 33 U.S. Patents issued.


  • Ph.D. Organic Chemistry, The Ohio State University, Columbus, OH
  • B.S. Chemistry, The Ohio State University, Columbus, OH
Save Resume #1603
to Contact Form?

You must first click "Yes" to save this resume

Submit Request

You have no Saved Resumes

Add resumes within our various Ares of Expertise by clicking "Add Resume(s)" below.

Add Resume(s)